Evidence map›Paper›PMID 42077643›Full record

ArticleClinical Medicine Insights. Cardiology2026

Best Practices and Key Barriers for Amyloidosis Patient Care at US Specialized Amyloidosis Centers: An Analysis by ARC-ASPIRE.

Jose Nativi-Nicolau, Johana Fajardo, Alyssa Galloway, Sami Khella, Nisith Kumar, Michaela Liedtke, Isabelle Lousada, Tiffany Patrick, Colleen Moffitt, Lori Klein and 3 more

Abstract read
In one paragraph

Article in Clinical Medicine Insights. Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jose Nativi-NicolauMayo Clinic, FL, USA.ORCID https://orcid.org/0000-0002-5481-2122
Johana FajardoDuke University Hospital, NC, USA.
Alyssa GallowayBridgeBio, CA, USA.
Sami KhellaUniversity of Pennsylvania School of Medicine, PA, USA.
Nisith KumarAmyloidosis Reserach Consortium (ARC) - Amyloidosis Stakeholder Partnerships for Impact, Reach & Equity (ASPIRE), MA, USA.ORCID https://orcid.org/0000-0003-0722-5432
Michaela LiedtkeStanford Health Care, CA, USA.
Isabelle LousadaAmyloidosis Research Consortium (ARC), MA, USA.
Tiffany PatrickAmyloidosis Reserach Consortium (ARC) - Amyloidosis Stakeholder Partnerships for Impact, Reach & Equity (ASPIRE), MA, USA.
Colleen MoffittAmyloidosis Reserach Consortium (ARC) - Amyloidosis Stakeholder Partnerships for Impact, Reach & Equity (ASPIRE), MA, USA.
Lori KleinPutnam Associates, MA, USA.ORCID https://orcid.org/0009-0005-1480-7125
Gabriela TamarizAmyloidosis Reserach Consortium (ARC) - Amyloidosis Stakeholder Partnerships for Impact, Reach & Equity (ASPIRE), MA, USA.
Karthikeyan VeeraraghavaluAmyloidosis Reserach Consortium (ARC) - Amyloidosis Stakeholder Partnerships for Impact, Reach & Equity (ASPIRE), MA, USA.
Alexandra Haddad-AnguloAmyloidosis Reserach Consortium (ARC) - Amyloidosis Stakeholder Partnerships for Impact, Reach & Equity (ASPIRE), MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Amyloidosis is a group of rare diseases that often manifest in multi-organ symptoms requiring an effective multidisciplinary team of care providers to manage. This study aimed to identify the best practices and key barriers to patient-centric care at US specialized amyloidosis centers (SACs) which have emerged as central hubs for multidisciplinary amyloidosis care. Methods: We conducted and analyzed interviews with 77 stakeholders of amyloidosis diseases, including specialist physicians from 17 SACs across the US, patients, patient advocacy group representatives, and referring physicians. Results: The most commonly mentioned best practices were patient-centric multidisciplinary care, timely intake of new high-risk patients, and responsiveness to patient questions. Expanding local physician education was noted as critical to earlier diagnosis. Fifteen out of 17 SACs are actively involved in clinical trials for amyloidosis treatments. Key barriers to care identified were patient distance to SACs, limited medical records and data sharing, and insurance hurdles. Most SACs keep track of metrics, such as patient volume, patient demographics, time to first appointment, as part of internal or in external registries to measure progress. Conclusion: These findings offer practical insights for optimizing amyloidosis care and highlight the structural and informational gaps that must be addressed to improve access and outcomes.

Indexed as

best practicescenters of excellencecoordinated carelight chain amyloidosismultidisciplinary carepatient-centric caretransthyretin amyloidosis

Identifiers

PMID42077643
PMCPMC13133438

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.